Duchenne Muscular Dystrophy Treatment Pipeline

Investigational Agent Therapeutic Class Expected FDA Decision Date
Drisapersen
Mutation corrector exon 51-skipping
December 27, 2015
Eteplirsen
Mutation corrector exon 51-skipping
February 26, 2016
Ataluren
Mutation corrector, nonsense read-through
2016
Deflazacort
Glucocorticoid
2016
Idebenone
Ion-channel modulator for cardiomyopathy
2016